DAISY FISHER: Open Payments
NPI 1114172939 · CHEVY CHASE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,244 in 54 payments from 15 companies in 2025. Trend: 2023 $2,299 · 2024 $1,130 · 2025 $1,244
Food & beverage: $1,145Education: $99
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 12 | $223 |
| Janssen Biotech, Inc. | 3 | $138 |
| Novartis Pharmaceuticals Corporation | 5 | $129 |
| Organon LLC | 4 | $104 |
| Galderma Laboratories, L.P. | 5 | $101 |
| ABBVIE INC. | 5 | $91 |
| PFIZER INC. | 4 | $85 |
| E.R. Squibb & Sons, L.L.C. | 4 | $73 |
| Regeneron Healthcare Solutions, Inc. | 2 | $54 |
| Incyte Corporation | 2 | $51 |
Products named: OTEZLA, TREMFYA, SKYRIZI, CIBINQO, DUPIXENT, Sotyktu, AKLIEF, Opzelura.
Industry payments across MD — which companies pay providers there.
